News
Videos from Patient Education Day on NETs from the SNMMI Annual Meeting
Philidelphia, June 2018
Introduction to Theranostic from Zentralklink Bad Berka
As of January 2020, Dr. Baum will be located at the THERANOSTICS CENTER FOR RADIOMOLECULAR PRECISION ONCOLOGY in Wiesbaden (very close to Frankfurt/Main airport (20 minutes by car or commuter train)). Dr. Baum will have full access to complete diagnostic and treatment facilities.
As of December 15, 2019, please use the following contact information:
Professor Dr. Richard P. Baum, MD, PhD
THERANOSTICUM Frankfurt-Wiesbaden
at DKD Clinic
Aukammallee 33
65191 Wiesbaden, Germany
1/26/18 - Advanced Accelerator Applications (AAA) Receives FDA Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine
AAA announced that the Federal Drug Administration (FDA) has approved the new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Click here to
"It shrinks tumors in about a third of cases significantly, and it lasts on average about two to three years," said Strosberg."Even though you get tumor shrinkage, you mostly get disease progression that stabilizes," said Dr. Thomas O'Dorisio, professor of medicine at the University of Iowa in Iowa City. Experts believe the FDA will eventually approve PRRT.
"The data are coming out slowly. There's never been a phase 3